Shopping Cart
- Remove All
- Your shopping cart is currently empty
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $228 | In Stock | |
5 mg | $589 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis. |
Targets&IC50 | GPVI-Fc:1.37 μg/mL |
In vitro | Inhibited the binding of GPVI-Fc to collagen immobilized on microtiter plates, glenzocimab (0-100,000 ng/mL) demonstrated an IC50 of 1.37 μg/mL[2]. |
In vivo | Glenzocimab ( 1-8 mg / kg ; i.v. ) inhibited collagen-induced platelet aggregation in cynomolgus monkeys [ 2 ]. |
Alias | ACT017 |
Molecular Weight | 48.29 kDa |
Cas No. | 2101829-58-5 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.